Evolution of the Average Target: XP Inc.

Evolution of the Target Price: XP Inc.

Changes in Analyst Recommendations: XP Inc.

6c88df5f.R6EC5klFFZbnLT4PZTMRbAfvvmE2aTMRMF9803HHabs.LflRnHghZMaIRA1eKmFbIE6iyS5bMWRkXxk9qQeAItoW6zGwPRxcwdAaaw~85b75dc1dc8400b4ff64837bbedbdc5b
08-31 Itau BBA Upgrades XP to Outperform From Market Perform, Adjusts PT to $22 From $19 MT
04-02 UBS Adjusts Price Target on XP to $28 From $25, Maintains Buy Rating MT
01-20 Jefferies Initiates XP at Buy With $22 Price Target MT
12-16 UBS Adjusts XP Price Target to $25 From $23, Maintains Buy Rating MT
25-10-16 UBS Adjusts Price Target on XP to $23 From $24, Maintains Buy Rating MT
25-06-23 XP Shares Drop After Downgrade From Itau BBA MT
25-06-23 Itau BBA Downgrades XP to Market Perform From Outperform, Adjusts Price Target to $21 From $20 MT
25-06-10 UBS Adjusts XP Price Target to $24 From $17, Maintains Buy Rating MT
25-06-04 Goldman Sachs Upgrades XP to Buy From Neutral, $23 Price Target MT
25-05-13 XP Shares Rise After Morgan Stanley Upgrades to Overweight From Equalweight MT
25-05-13 Morgan Stanley Upgrades XP to Overweight From Equalweight, Adjusts Price Target to $24 From $18 MT
25-04-07 UBS Adjusts Price Target on XP to $17 From $16, Keeps Buy Rating MT
25-03-18 Itau BBA Initiates XP at Outperform With $20 Price Target MT
25-01-24 XP Shares Rise After Upgrade From UBS MT
25-01-24 UBS Upgrades XP to Buy From Neutral, Cuts Price Target to $16 From $19 MT
24-12-10 BofA Securities Downgrades XP to Neutral From Buy, Price Target is $16 MT
24-11-25 UBS Cuts Price Target on XP to $19 From $21, Maintains Neutral Rating MT
24-07-11 UBS Downgrades XP to Neutral From Buy, Cuts Price Target to $21 From $30 MT
24-07-05 Bradesco BBI Downgrades XP to Neutral From Outperform, Cuts Price Target to $19 From $31 MT
24-06-05 Citigroup Adjusts Price Target on XP to $27 From $29, Maintains Buy Rating MT
24-04-30 XP Shares Decline After Goldman Sachs Downgrade MT
24-04-30 Goldman Sachs Downgrades XP to Neutral From Buy, Cuts Price Target to $23 From $30 MT
24-04-23 Morgan Stanley Downgrades XP to Equalweight From Overweight, Adjusts Price Target to $24 From $31 MT
24-03-22 Citigroup Adjusts Price Target on XP to $29 From $28, Maintains Buy Rating MT
23-12-11 UBS Adjusts XP Price Target to $30 From $31, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+42.57%
+41.03%
+18.65%
+39.07%
+36.75%
+15.06%
- +1.46%
Average +27.80%
Weighted average by Cap. +32.58%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
102.09BRL
Average target price
119.04BRL
Spread / Average Target
+16.60%
High Price Target
134.16BRL
Spread / Highest target
+31.41%
Low Price Target
103.67BRL
Spread / Lowest Target
+1.54%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-